You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


BMS’ Zeposia hits the mark in ulcerative colitis

Bristol Myers Squibb’s oral S1P receptor modulator Zeposia hit both primary endpoints in a phase III trial as an induction and maintenance therapy in adult patients with moderate-to-severe ulcerative colitis (UC).